Date: July 27, 2023 Your Name: Bowen Li Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial _XNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_XNone	

-	Devenent en here energie fer	X No.	
5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X _None	
	testimony		
7	Support for attending	X_None	
	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
12	services	N. News	
13	Other financial or non-	_ XNone	
	financial interests		

No conflict of interest to declare.

## Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Ziqi Jia Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initialXNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_XNone	

-	Devenent en here energie fer	X No.	
5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X _None	
	testimony		
7	Support for attending	X_None	
	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
12	services	N. News	
13	Other financial or non-	_ XNone	
	financial interests		

No conflict of interest to declare.

## Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Zhicheng Huang Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial _XNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_XNone	

-	Devenent en here energie fer	X No.	
5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X _None	
	testimony		
7	Support for attending	X_None	
	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
12	services	N. News	
13	Other financial or non-	_ XNone	
	financial interests		

No conflict of interest to declare.

## Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Jianchao Xue Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial _XNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_XNone	

5       Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events      XNone         6       Payment for expert testimony      XNone         7       Support for attending meetings and/or travel      XNone	
Iectures, presentations, speakers bureaus, manuscript writing or educational events	
speakers bureaus, manuscript writing or educational events    XNone       6     Payment for expert testimony    XNone       7     Support for attending    XNone	
manuscript writing or educational events    X_None       6     Payment for expert testimony    X_None       7     Support for attending    X_None	
educational events    X_None       6     Payment for expert testimony    X_None       7     Support for attending    X_None	
6       Payment for expert testimony      X_None         7       Support for attending      X_None	
testimony	
7     Support for attending    XNone	
meetings and/or travel	
8 Patents planned, issued orXNone	
pending	
9 Participation on a DataX_None	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary roleX_None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock optionsX_None	
12 Receipt of equipment,XNone	
materials, drugs, medical	
writing, gifts or other	
services	
13   Other financial or non-  XNone	
financial interests	

No conflict of interest to declare.

## Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Yadong Wang Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial _XNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_XNone	

5       Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events      XNone         6       Payment for expert testimony      XNone         7       Support for attending meetings and/or travel      XNone	
Iectures, presentations, speakers bureaus, manuscript writing or educational events	
speakers bureaus, manuscript writing or educational events    XNone       6     Payment for expert testimony    XNone       7     Support for attending    XNone	
manuscript writing or educational events    X_None       6     Payment for expert testimony    X_None       7     Support for attending    X_None	
educational events    X_None       6     Payment for expert testimony    X_None       7     Support for attending    X_None	
6       Payment for expert testimony      X_None         7       Support for attending      X_None	
testimony	
7     Support for attending    XNone	
meetings and/or travel	
8 Patents planned, issued orXNone	
pending	
9 Participation on a DataX_None	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary roleX_None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock optionsX_None	
12 Receipt of equipment,XNone	
materials, drugs, medical	
writing, gifts or other	
services	
13   Other financial or non-  XNone	
financial interests	

No conflict of interest to declare.

## Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Chao Guo Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial _XNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_XNone	

-	Devenent en here energie fer	X No.	
5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X _None	
	testimony		
7	Support for attending	X_None	
	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
12	services	N. News	
13	Other financial or non-	_ XNone	
	financial interests		

No conflict of interest to declare.

## Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Xiaoyan Si Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial _XNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_XNone	

5       Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events      XNone         6       Payment for expert testimony      XNone         7       Support for attending meetings and/or travel      XNone	
Iectures, presentations, speakers bureaus, manuscript writing or educational events	
speakers bureaus, manuscript writing or educational events    XNone       6     Payment for expert testimony    XNone       7     Support for attending    XNone	
manuscript writing or educational events    X_None       6     Payment for expert testimony    X_None       7     Support for attending    X_None	
educational events    X_None       6     Payment for expert testimony    X_None       7     Support for attending    X_None	
6       Payment for expert testimony      X_None         7       Support for attending      X_None	
testimony	
7     Support for attending    XNone	
meetings and/or travel	
8 Patents planned, issued orXNone	
pending	
9 Participation on a DataX_None	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary roleX_None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock optionsX_None	
12 Receipt of equipment,XNone	
materials, drugs, medical	
writing, gifts or other	
services	
13   Other financial or non-  XNone	
financial interests	

No conflict of interest to declare.

## Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Zexin Chen Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

v ru n n	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Il support for the present	<pre>Time frame: Since the initial _ XNone</pre>	
nedical writing, article		
	Time frame: past	36 months
irants or contracts from	_XNone	
oyalties or licenses	XNone	
onsulting fees	_XNone	
rocessing charges, etc.) Io time limit for this item.	_XNone	36 months

-	Devenent en here energie fer	X No.	
5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X _None	
	testimony		
7	Support for attending	X_None	
	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
12	services	N. News	
13	Other financial or non-	_ XNone	
	financial interests		

No conflict of interest to declare.

## Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Ji Li Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial _XNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_XNone	

5       Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events      XNone         6       Payment for expert testimony      XNone         7       Support for attending meetings and/or travel      XNone	
Iectures, presentations, speakers bureaus, manuscript writing or educational events	
speakers bureaus, manuscript writing or educational events    XNone       6     Payment for expert testimony    XNone       7     Support for attending    XNone	
manuscript writing or educational events    X_None       6     Payment for expert testimony    X_None       7     Support for attending    X_None	
educational events    X_None       6     Payment for expert testimony    X_None       7     Support for attending    X_None	
6       Payment for expert testimony      X_None         7       Support for attending      X_None	
testimony	
7     Support for attending    XNone	
meetings and/or travel	
8 Patents planned, issued orXNone	
pending	
9 Participation on a DataX_None	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary roleX_None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock optionsX_None	
12 Receipt of equipment,XNone	
materials, drugs, medical	
writing, gifts or other	
services	
13   Other financial or non-  XNone	
financial interests	

No conflict of interest to declare.

## Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Rongrong Chen Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Support for attending meetings and/or travel	X_None	
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Geneplus-Beijing	
	financial interests	201000000000	

Rongrong Chen is from Geneplus-Beijing.

## Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Zhixin Bie Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initialXNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_XNone	

-	Devenent en here energie fer	X No.	
5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X _None	
	testimony		
7	Support for attending	X_None	
	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
12	services	N. News	
13	Other financial or non-	_ XNone	
	financial interests		

No conflict of interest to declare.

## Please place an "X" next to the following statement to indicate your agreement:

Date: July 14, 2023 Your Name: Andrea De Giglio Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4–ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		<b>-</b>	
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
0	testimony		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10		V. News	
10		XNone	
	-		
11		X None	
12		XNone	
	_		
12		X None	
13			
	Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options		

No conflict of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

Date: July 14, 2023 Your Name: Petros Christopoulos Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4–ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
	No time limit for this item.	<b>-</b> :	
		Time frame: past	
2	Grants or contracts from any	Roche	research grant (to institution)
1 -		Roene	
	entity (if not indicated in	Amgen	research grant (to institution)
	entity (if not indicated in	Amgen	research grant (to institution)
	entity (if not indicated in	Amgen Boehringer Ingelheim	research grant (to institution) research grant (to institution)
	entity (if not indicated in	Amgen Boehringer Ingelheim Takeda	research grant (to institution) research grant (to institution) research grant (to institution)
	entity (if not indicated in	Amgen Boehringer Ingelheim Takeda Novartis	research grant (to institution) research grant (to institution) research grant (to institution) research grant (to institution)
	entity (if not indicated in	Amgen Boehringer Ingelheim Takeda Novartis Merck	research grant (to institution) research grant (to institution) research grant (to institution) research grant (to institution) research grant (to institution)
3	entity (if not indicated in	Amgen Boehringer Ingelheim Takeda Novartis Merck	research grant (to institution) research grant (to institution) research grant (to institution) research grant (to institution) research grant (to institution)

	lectures, presentations,	Takeda	speaker's honoraria to myself
	speakers bureaus,	Gilead	speaker's honoraria to myself
	manuscript writing or	AstraZeneca	speaker's honoraria to myself
	educational events	Astrazeneca Thermo Fisher	
			speaker's honoraria to myself
		Janssen	speaker's honoraria to myself
		Pfizer	speaker's honoraria to myself
		Novartis	speaker's honoraria to myself
6	Payment for expert	_XNone	
	testimony		
7	Support for attending	AstraZeneca	to myself
	meetings and/or travel	Pfizer	to myself
		Janssen	to myself
		Daiichi Sankyo	to myself
		Takeda	to myself
		Novartis	to myself
		Eli Lilly	to myself
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	Pfizer	advisory board
	Safety Monitoring Board or Advisory Board	Chugai	advisory board
		Boehringer Ingelheim	advisory board
		Takeda	advisory board
		Novartis	advisory board
		AstraZeneca	advisory board
		MSD	advisory board
		Roche	advisory board
10	Leadership or fiduciary role in	XNone	
	other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Petros Christopoulos has received research funding from AstraZeneca, Merck, Amgen, Boehringer Ingelheim, Novartis, Roche, and Takeda, speaker's honoraria from AstraZeneca, Gilead, Janssen, Novartis, Roche, Pfizer, Thermo Fisher, Takeda, support for attending meetings from AstraZeneca, Eli Lilly, Daiichi Sankyo, Janssen, Novartis, Pfizer, Takeda, and personal fees for participating to advisory boards from AstraZeneca, Boehringer Ingelheim, Chugai, Pfizer, Novartis, MSD, Takeda and Roche, all outside the submitted work.

#### Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Naixin Liang Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	the Chinese Society of Clinical Oncology Fund (Nos. Y-MSDPU2021-0190 and Y-MSD2020-0270)	research grant (to institution)
		the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2020-I2M- C&T-A-003)	research grant (to institution)

3	Royalties or licenses	_ XNone
4	Consulting fees	XNone
5	Payment or honoraria for	X_None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	X_None
	testimony	
7	Course and fair and the	
7	Support for attending meetings and/or travel	X_None
8	Patents planned, issued or	X_None
	pending	
9	Participation on a Data	X_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	X_None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	X_None
12	Receipt of equipment,	_ XNone
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	

Naixin Liang has received research funding from the Chinese Society of Clinical Oncology Fund (Nos. Y-MSDPU2021-0190 and Y-MSD2020-0270), and the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2020-I2M- C&T-A-003), all outside the submitted work.

#### Please place an "X" next to the following statement to indicate your agreement:

Date: July 27, 2023 Your Name: Shanqing Li Manuscript Title: Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	the National High Level Hospital Clinical Research Funding (No. 2022- PUMCH-B-011)	research grant (to institution)
3	Royalties or licenses	_XNone	

4	Consulting fees	_ XNone	
5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
•	testimony		
7	Support for attending meetings and/or travel	X_None	
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X None	
9	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	V. Nene	
11	Stock or stock options	X_None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ XNone	
	financial interests		

Shanqing Li has received research funding from the National High Level Hospital Clinical Research Funding (No. 2022-PUMCH-B-011), outside the submitted work.

## Please place an "X" next to the following statement to indicate your agreement: